Cold-Chain Shipping for Peptides: A Clinic Receiving Guide
Prepare for temperature-sensitive deliveries, document receipt, quarantine questionable stock, and resolve shipping exceptions with the responsible quality team.
For facility-specific purchasing requirements, visit our wellness clinics sourcing guide. This article covers procurement, not treatment protocols.
Confirm product-specific conditions before dispatch
Obtain written transport and storage requirements for the exact preparation. Do not assume every peptide shares a temperature range or can tolerate freezing. Ask what evidence accompanies the shipment and who reviews exceptions.
Schedule delivery for trained coverage
Confirm the receiving address, delivery hours, holiday coverage, and a contact for delays. Make sure appropriate storage is ready before arrival. A delivery notification is not a substitute for someone accepting and checking the package.
Create a receipt record
Record arrival time, package condition, product and lot identifiers, quantity, dating, and any required monitor results. Preserve photographs and transport evidence when something is wrong. Compare the shipment to the purchase order before adding it to usable stock.
Quarantine questionable inventory
Keep damaged or potentially temperature-exposed stock separate and prevent clinical use while it is assessed. Do not assume returning it to refrigeration reverses an excursion. Obtain a documented decision from the responsible qualified reviewer using product-specific information.
Close the exception and improve the process
Record the final disposition, supplier authorization, and any replacement or credit. Investigate recurring delivery delays and adjust scheduling or packaging arrangements with the supplier. A delivery that feels cold does not by itself prove that labeled conditions were maintained.
What to do next
Record unresolved questions and the evidence your clinical or quality reviewer needs before ordering. Use the wellness clinics purchasing page to prepare a facility-specific inquiry. Product mentions do not confirm stock, a legal supply pathway, or suitability for patient care.
Regulatory sources and purchasing limits
Compounded drugs are not FDA-approved. Facility registration does not establish approval or eligibility for every preparation. Verify the exact product, source, applicable federal requirements, and state rules before ordering. This is procurement education, not medical or legal advice.
- FDA: bulk substances used under section 503B, including restrictions and interim policies.
- FDA: GLP-1 compounding and shortage updates.
- FDA: safety concerns for certain compounding substances.